维生素 D 检测市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球维生素 D 检测市场价值为 13 亿美元，预计将以 7.3% 的复合年增长率成长，到 2034 年达到 30 亿美元。

这一增长受到全球维生素D缺乏症盛行率上升、预防性医疗保健日益受到重视以及诊断检测需求不断增长的影响。先进技术不断融入医疗保健系统，加速了维生素D诊断方法的普及。随着糖尿病、自体免疫疾病、心血管疾病和骨质疏鬆症等慢性疾病的发生率上升，维生素D检测正成为临床工作流程中的关键组成部分。医疗保健机构正在将这些检测纳入常规诊断，以更准确地管理维生素D缺乏症并监测补充结果。诊断实验室、支付方和数位健康平台正在转向液相层析串联质谱法 (LC-MS/MS)、酶联免疫吸附试验 (ELISA) 和化学发光免疫分析法等解决方案，以提高准确性并更好地监测患者。这支持了向个人化医疗保健的重大转变，其中早期检测起着关键作用。医院、诊所甚至家庭机构均可进行维生素D检测，有助于提高维生素D的可近性。对慢性病预防、妇幼保健和老年护理计画的日益关注，进一步支持了市场持续的成长轨迹。

25-羟基维生素D检测市场在2024年占据了86.2%的市场份额，因为它仍然是评估血液中维生素D水平的首选标准。预计到2034年，该市场规模将达到26亿美元，复合年增长率为7.6%。其用途涵盖多种临床应用，包括慢性病管理、常规健康体检、老年护理和营养评估。此检测被广泛用于评估日照不足、饮食摄取量低或代谢紊乱影响维生素D吸收的个体的维生素D缺乏症。它在全民筛检和标靶诊断中的作用将继续巩固其市场主导地位。

化学发光免疫分析 (CLIA) 领域在 2024 年占据 43.5% 的市场份额，预计到 2034 年将达到 13 亿美元。化学发光免疫分析 (CLIA) 检测需求的不断增长，得益于其优于传统免疫分析方法的灵敏度和精确度。 CLIA 能够准确定量关键维生素 D 代谢物，而这些代谢物是评估维生素 D 缺乏相关风险的重要指标。由于其可靠性、速度和可扩展的通量，CLIA 在中心实验室和即时检测机构的应用日益广泛。

2024年，北美维生素D检测市场占据37.7%的市场份额，这得益于先进的医疗基础设施、患者认知度的提升以及积极的筛检措施。该地区尤其受到普遍存在的维生素D缺乏症的影响，尤其是在日照较少的地区。因此，检测越来越多地被纳入常规健康评估。医生经常建议患有长期​​疾病的患者进行这些检测，这促进了需求的成长。广泛的保险覆盖、政府的健康宣传活动以及日益增长的家庭诊断服务，进一步加速了美国和加拿大市场的扩张。

影响全球维生素 D 检测市场的关键公司包括雅培、赛默飞世尔科技、罗氏、丹纳赫（贝克曼库尔特）、迈瑞医疗国际、NanoSpeed Diagnostics、西门子、Diasorin、朗道实验室、Bio-Rad 实验室、东曹、Qualigen Therapeutics、欧蒙、生物梅里埃和 NanoAEnek。为了巩固市场地位，维生素 D 检测市场的领导者正在实施一系列策略性倡议。许多企业专注于透过推出高灵敏度、可缩短週转时间的新一代检测试剂盒来扩展其诊断产品组合。企业也正在投资自动化和基于人工智慧的分析技术，以提高工作流程效率和资料准确性。透过与分销商合作和本地製造，企业正优先考虑向高成长地区进行地理扩张。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
  • 零件和技术供应商
  • 诊断设备与试剂盒製造商
  • 每个阶段的增值
• 产业衝击力
  • 成长动力
    • 维生素D缺乏症盛行率不断上升
    • 消费者意识不断提高
    • 公共卫生运动和报销政策的兴起
    • 不断进步的技术
  • 产业陷阱与挑战
    • 先进诊断方法成本高昂
  • 市场机会
    • 扩展到即时诊断和家庭检测
    • 进军新兴市场
• 成长潜力分析
• 监管情景
  • 北美洲
  • 欧洲
  • 亚太地区
• 报销场景
• 技术格局
  • 当前的技术趋势
  • 新兴技术
• 未来市场趋势
• 2024年定价分析
• 专利格局
  • 专利持有人分析
• 临床指引和标准化
• 投资与融资趋势
• 流行病学情景
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
  • 全球的
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 多边环境协定
• 竞争定位矩阵
• 主要市场参与者的竞争分析
• 关键进展
  • 併购
  • 伙伴关係与合作
  • 推出新服务类型
  • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 25-羟基维生素D检测
• 1,25-二羟基维生素D检测

第六章：市场估计与预测：按技术，2021 - 2034 年

• 主要趋势
• 化学发光免疫分析
• 酵素连结免疫吸附试验
• 液相层析质谱联用
• 放射免疫分析法
• 其他技术

第七章：市场估计与预测：按适应症，2021 - 2034

• 主要趋势
• 维生素 D 缺乏症
• 骨质疏鬆症
• 心血管
• 疳
• 甲状腺疾病
• 其他适应症

第 8 章：市场估计与预测：按患者，2021 - 2034 年

• 主要趋势
• 成人
• 儿科

第九章：市场估计与预测：按测试类型，2021 - 2034

• 主要趋势
• 常规测试
• 即时检验

第 10 章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 诊断实验室
• 医院
• 居家护理
• 其他最终用途

第 11 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：公司简介

• Abbott
• bioMerieux
• Bio-Rad Laboratories
• Danaher (Beckman Coulter)
• Diasorin
• EUROIMMUN
• Roche
• Mindray Medical International
• NanoEnTek
• NanoSpeed Diagnostics
• Qualigen Therapeutics
• Randox Laboratories
• Siemens
• Thermo Fisher Scientific
• Tosoh

The Global Vitamin D Testing Market was valued at USD 1.3 billion in 2024 and is estimated to grow at a CAGR of 7.3% to reach USD 3 billion by 2034.

The growth is influenced by the increasing prevalence of vitamin D deficiency worldwide, a greater focus on preventive healthcare, and rising demand for diagnostic testing. The continued integration of advanced technologies into healthcare systems is accelerating the adoption of vitamin D diagnostics. With chronic illnesses such as diabetes, autoimmune disorders, cardiovascular diseases, and osteoporosis on the rise, vitamin D testing is becoming a critical part of clinical workflows. Healthcare providers are incorporating these tests into routine diagnostics to manage deficiencies and monitor supplementation outcomes more accurately. Diagnostic labs, payers, and digital health platforms are turning to solutions like LC-MS/MS, ELISA, and chemiluminescence immunoassays for enhanced accuracy and patient monitoring. This is supporting a major shift toward personalized healthcare, where early detection plays a key role. The availability of vitamin D testing in hospitals, clinics, and even at-home setups contributes to increasing accessibility. The expanding focus on chronic disease prevention, maternal and child health, and elderly care programs is further supporting the market's consistent growth trajectory.

The 25-hydroxy vitamin D test segment held 86.2% share in 2024, as it remains the preferred standard for evaluating vitamin D levels in the blood. This segment is projected to reach USD 2.6 billion by 2034, growing at a CAGR of 7.6%. Its use spans multiple clinical applications, including chronic disease management, routine wellness checkups, elderly care, and nutritional assessments. The test is widely adopted to assess deficiency in individuals with limited sunlight exposure, low dietary intake, or metabolic disorders affecting vitamin D absorption. Its role in both population-wide screenings and targeted diagnostics continues to solidify its market dominance.

The CLIA segment held a 43.5% share in 2024 and is expected to reach USD 1.3 billion by 2034. The growing demand for chemiluminescence immunoassay testing is driven by its superior sensitivity and precision over traditional immunoassay methods. CLIA enables accurate quantification of key vitamin D metabolites, which are essential markers in assessing deficiency-related risks. Its adoption is increasing across both centralized labs and point-of-care testing setups due to its reliability, speed, and scalable throughput.

North America Vitamin D Testing Market held a 37.7% share in 2024, driven by advanced healthcare infrastructure, high patient awareness, and proactive screening initiatives. The region is particularly impacted by widespread vitamin D deficiency, especially in areas with reduced sun exposure. As a result, testing is increasingly integrated into routine health evaluations. Physicians regularly recommend these tests for patients with long-term conditions, contributing to increased demand. Widespread insurance coverage, government health campaigns, and growing home-based diagnostics are further accelerating market expansion across the US and Canada.

Key companies shaping the Global Vitamin D Testing Market include Abbott, Thermo Fisher Scientific, Roche, Danaher (Beckman Coulter), Mindray Medical International, NanoSpeed Diagnostics, Siemens, Diasorin, Randox Laboratories, Bio-Rad Laboratories, Tosoh, Qualigen Therapeutics, EUROIMMUN, bioMerieux, and NanoEnTek. To strengthen their foothold, leading players in the vitamin D testing market are implementing a range of strategic initiatives. Many are focused on expanding their diagnostic portfolios by launching highly sensitive, next-generation assay kits that offer faster turnaround times. Companies are also investing in automation and AI-based analytics for enhanced workflow efficiency and data accuracy. Geographic expansion into high-growth regions is being prioritized through distributor partnerships and local manufacturing.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Technique trends
  • 2.2.4 Indication trends
  • 2.2.5 Patient trends
  • 2.2.6 Test type trends
  • 2.2.7 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Component & technology suppliers
  • 3.1.2 Diagnostic device & kit manufacturers
  • 3.1.3 Value addition at each stage
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of vitamin D deficiency disorders
    • 3.2.1.2 Rising awareness among consumers
    • 3.2.1.3 Rise in public health campaigns and reimbursement policies
    • 3.2.1.4 Increasing technological advancements
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced diagnostic methods
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion into point-of-care and home testing
    • 3.2.3.2 Growth into emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory scenario
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
  • 3.6.1 Current technological trends
  • 3.6.2 Emerging technologies
• 3.7 Future market trends
• 3.8 Pricing analysis, 2024
• 3.9 Patent landscape
  • 3.9.1 Patent holder analysis
• 3.10 Clinical guidelines & standardization
• 3.11 Investment & funding trends
• 3.12 Epidemiology scenario
• 3.13 Porter's analysis
• 3.14 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 Latin America
  • 4.3.6 MEA
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New service type launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 25-hydroxy vitamin D test
• 5.3 1,25-dihydroxy vitamin D test

Chapter 6 Market Estimates and Forecast, By Technique, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 CLIA
• 6.3 ELISA
• 6.4 LC-MS
• 6.5 Radioimmunoassay
• 6.6 Other techniques

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Vitamin D deficiency
• 7.3 Osteoporosis
• 7.4 Cardiovascular
• 7.5 Rickets
• 7.6 Thyroid disorders
• 7.7 Other indications

Chapter 8 Market Estimates and Forecast, By Patient, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Adult
• 8.3 Pediatric

Chapter 9 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Conventional test
• 9.3 Point-of-care test

Chapter 10 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Diagnostic laboratories
• 10.3 Hospitals
• 10.4 Homecare
• 10.5 Other end use

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 Abbott
• 12.2 bioMerieux
• 12.3 Bio-Rad Laboratories
• 12.4 Danaher (Beckman Coulter)
• 12.5 Diasorin
• 12.6 EUROIMMUN
• 12.7 Roche
• 12.8 Mindray Medical International
• 12.9 NanoEnTek
• 12.10 NanoSpeed Diagnostics
• 12.11 Qualigen Therapeutics
• 12.12 Randox Laboratories
• 12.13 Siemens
• 12.14 Thermo Fisher Scientific
• 12.15 Tosoh